Trial Profile
A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Flutamide; Sargramostim
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Jul 2023 Primary endpoint has not been met, (Time to Treatment Failure), as per Results published in the Oncologist
- 05 Jul 2023 Results published in the Oncologist
- 09 Jun 2017 Status changed from active, no longer recruiting to completed.